#+TITLE: Laboratory Methods for Quantitative Acylcarnitines in Biological Matrices
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

* Introduction
- carnitine (\beta-hydroxy-\gamma-N-trimethylaminobutyric acid) is
  an endogenous quaternary ammonium compound synthesized from lysine
  and methionine

#+BEGIN_EXPORT LaTeX
\begin{center}
\chemnameinit{}
\chemname{\chemfig{H3C-N^{+}([2]-CH3)([6]-CH3)-CH2-C([2]-H)([6]-OH)-CH_2-C([1]=O)([7]-O^{-})}}{\small carnitine}
\hspace{3em}
\chemname{\chemfig{H3C-N^{+}([2]-CH3)([6]-CH3)-CH2-C([2]-H)([6]-O-C([0]=O)-{\color{red}R})-CH_2-C([1]=O)([7]-O^{-})}}{\small acylcarnitine}
\end{center}
#+END_EXPORT

- carnitine has been described as a "conditionally essential"
  nutrient for humans
- exogenous carnitine is required to maintain plasma carnitine
  concentrations in humans of all ages especially
  - infants (premature and full-term)
  - patients on long-term parenteral nutrition
  - children
- primary function is to shuttle long chain fatty acids to the
  mitochondrial matrix for \beta-oxidation
- acylcarnitines are markers for FAODs and OAs


#+CAPTION[]: Acylcarnitine Panel
#+NAME: tab:acpanel
| carbons  | acylcarnitine             | disorder                           |
|----------+---------------------------+------------------------------------|
| C0       | free                      | CUD                                |
| C2       | acetyl                    | CUD                                |
| C3       | propionyl                 | PA, MMA, SUCLA2                    |
| C4       | butyryl                   | SCAD, IBDH, GA2, EE                |
|          | isobutyryl                |                                    |
| C5:1     | tiglyl                    | BKT, MCC, MHBD                     |
| C5       | isovaleryl                | IVA, GA2, EE                       |
|          | 2-methylbutyryl           | SBCAD                              |
|          | pivalyl                   | antibiotics                        |
| C4-OH    | 3-hydroxybutyrl           | SCHAD, ketosis                     |
| C6:1     | 3-methylglutaconyl        | MGA                                |
| C6       | hexanoyl                  | MCAD, MKAT, GA2                    |
| C5-OH    | 3-hydroxyisovaleryl       | biotinidase, HMGCL, MCC, MCD, MGA  |
|          | 2-methyl-3-hydroxybutyryl | BKT, MHBD                          |
| C7       | heptanoly                 | heptanoic acid treatment           |
| C8:1     | octenoyl                  |                                    |
| C8       | octanoyl                  | MCAD, M/SCHAD, MKAT, GA2           |
| C3-DC    | malonyl                   | malonic aciduria                   |
| C10:2    | decadienoyl               | DCR                                |
| C10:1    | decenoyl                  | MCAD                               |
| C10      | decanoyl                  | MCAD, GA2                          |
| C4-DC    | methylmalonyl             | MMA                                |
|          | succinyl                  | SUCLA2                             |
| C5-DC    | glutaryl                  | GA1                                |
| C10-OH   | 3-hydroxy decanoyl        | M/SCHAD, MKAT                      |
| C12:1    | dodecenoyl                |                                    |
| C12      | dodecanoyl                | GA2                                |
| C6-DC    | adipyl                    |                                    |
|          | 3-methylglutaryl          | HMGCL                              |
| C12-OH   | 3-hydroxy dodecanoyl      | LCHAD, TFP                         |
| C14:2    | tetradecadienoyl          |                                    |
| C14:1    | tetradecenoyl             | CACT, CPTII, GA2, VLCAD, LCAD, TFP |
| C14      | myristoyl                 | CACT, CPTII, GA2, VLCAD, LCAD, TFP |
| C8-DC    | suberyl                   |                                    |
| C14-OH   | 3-hydroxymyristoyl        | LCHAD, TFP                         |
| C16:1    | palmitoleyl               |                                    |
| C16      | palmitoyl                 | CACT, CPT2, CPT1, VLCAD, LCAD, TFP |
| C10-DC   | sebacyl                   |                                    |
| C16:1-OH | 3-hydroxy hexadecenoyl    | antibiotics                        |
| C16-OH   | 3-hydroxy hexadecanoyl    | LCHAD, TFP                         |
| C18:2    | linoleyl                  | CACT, CPT2, VLCAD, LCAD, TFP       |
| C18:1    | oleyl                     | CACT, CPT2, CPT1, VLCAD, LCAD, TFP |
| C18      | stearoyl                  | CACT, CPT2, CPT1, VLCAD, LCAD, TFP |
| C18:2-OH | 3-hydroxylinoleyl         |                                    |
| C18:1-OH | 3-hydroxyoleyl            | LCHAD,TFP                          |
| C18-OH   | 3-hydroxystearoyl         | LCHAD,TFP                          |
| C16-DC   | hexadecanedioyl           |                                    |

** Disorders Associated with Abnormal Acylcarnitine Profiles
- BKT :: beta-ketothiolase
- CACT :: carnitine-acylcarnitine translocase
- CPT :: carnitine palmitoyltransferase I and II
- DCR :: 2,4-dienoyl-CoA reductase
- EE :: ethylmalonic encephalopathy
- FIGLU :: formiminoglutamate
- GA1 :: glutaric acidemia type I (glutaryl-CoA dehydrogenase)
- GA2 :: glutaric acidemia type II (multiple acyl-CoA dehydrogenase)
- HMGCL :: 3-hydroxy 3-methylglutaryl-CoA lyase
- IBDH :: isobutyryl-CoA dehydrogenase
- IVA :: isovaleric acidemia (isovaleryl-CoA dehydrogenase)
- LCHAD :: long-chain 3-hydroxy acyl-CoA dehydrogenase
- MCAD :: medium-chain acyl-CoA dehydrogenase
- MCC :: 3-methylcrotonyl-CoA carboxylase
- MCD :: multiple carboxylase (holocarboxylase)
- MGA :: 3-methylglutaconic aciduria type I (3-methylglutaconyl-CoA hydratase)
- MKAT :: medium-chain 3-ketoacyl-CoA thiolase
- MMA :: methylmalonic acidemias (MUT, CblC)
- MHBD :: 2-methyl 3-hydroxy butyryl-CoA dehydrogenase
- PA :: propionic acidemia (propionyl-CoA carboxylase)
- SBCAD :: short-branched-chain acyl-CoA dehydrongenase
- SCAD :: short-chain acyl-CoA dehydrogenase
- SCHAD :: short-chain 3-hydroxy acyl-CoA dehydrogenase
- SUCLA2 :: ATP-dependent-proteolysis-factor-formingsuccinyl-CoA synthetase
- TFP :: mitochondrial trifunctional protein
- VLCAD :: very long-chain acyl-CoA dehydrogenase


* Diagnostic FIA-MS/MS
** Sample Prep

- acylcarnitines in plasma are extracted into methanol 
- reconsituted and esterified as butyl esters with butanol-hydrogen
  chloride
- solvent delivery is via HPLC with no chromatography, called flow
  injection analysis
- 10 \micro{}L of sample extract is injected into a flowing stream
  operating at ~ 0.15 ml/min
  - 3 min integration per sample

#+BEGIN_EXPORT LaTeX
\chemnameinit{}
\definesubmol{x}{-[1,.6]-[7,.6]}
\definesubmol{y}{-[7,.6]-[1,.6]}
\definesubmol{d}{!y!y-[7,.6]{\color{red}COOH}}
\definesubmol{e}{!y!y}
\schemestart
\chemname{\chemfig{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!e)-[1]-[7]([7]=O)([1]-O^{-})}}{\small C5-carnitine}
\+
\chemname{\chemfig{HO!x!x}}{\small n-butanol}
\arrow{-U>[][{\small \ce{H2O}}]}
\chemname{\chemfig{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!e)-[1]-[7]([6]=O)-[1,.6]O!y!y}}{\small C5-carnitine, butyl ester}
\schemestop

\vspace{2em}

\schemestart
\chemname{\chemfig{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!d)-[1]-[7]([7]=O)([1]-O^{-})}}{\small C6DC-carnitine}
\+
\chemname{\chemfig{HO!x!x}}{\small n-butanol}
\arrow{-U>[][{\small \ce{2H2O}}]}
\chemname{\chemfig{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!e-[7,.6]O!x!x)-[1]-[7]([6]=O)-[1,.6]O!y!y}}{\small C6DC-carnitine, butyl ester}
\schemestop 
#+END_EXPORT

#+CAPTION[]:Rationale for Derivatization
#+NAME: fig:deriv
#+ATTR_LaTeX: :width 0.9\textwidth
[[file:./ac/figures/ionization.png]]

** FIA-MS/MS schematic
#+BEGIN_EXPORT LaTeX
\begin{center}
\begin{tikzpicture}[node distance=7em]
% nodes
\node(ms1)[ms]{MS1: Mass Filter};
\node(cc)[ms, right of=ms1]{Collision cell};
\node(ms2)[ms, right of=cc]{MS2: Mass Filter};
\node(ion)[ms, below of=ms1,yshift=3em]{Ionization};
\node(lc)[msw, below of=ion,yshift=3em]{Injection};
\node(detector)[ms, below of=ms2, yshift=3em]{Detector};
% arrows
\draw[arrow](lc) -- (ion);
\draw[arrow](ion) -- (ms1);
\draw[arrow](ms1) -- (cc);
\draw[arrow](cc) -- (ms2);
\draw[arrow](ms2) -- (detector);
\end{tikzpicture}
\end{center}
#+END_EXPORT

** Inlet table                                                     :noexport:

#+tblname: data-table
| Time |  Flow |  %A | %B |
|------+-------+-----+----|
|    0 |  1.00 | 100 |  0 |
|  0.3 | 0.095 | 100 |  0 |
|  1.2 | 0.100 | 100 |  0 |
| 1.55 | 0.500 | 100 |  0 |
| 1.85 | 0.100 | 100 |  0 |
|  2.5 | 0.100 | 100 |  0 |

** Precursor Ion Scan
- electrospray ionization in positive mode
- butylated acylcarnitines fragment to produce a characteristic ion with mass of 85 Da 
- precursor ion scan is used to identify molecules that fragment to form a 85 m/z molecule

#+BEGIN_EXPORT LaTeX
\begin{center}
\chemnameinit{}
\definesubmol{x}{-[1,.6]-[7,.6]}
 \chemname{\chemfig{H_{3}C-N^{+}([2]-CH_3)([6]-CH_{3})-CH_2-C([2]-H)([6]-O-C([0]=O)-{\color{red}R})-CH_2-C([2]=O)-O-CH_2-CH_2-CH_2-CH_3}}{\small acylcarnitine, butyl ester}

\vspace{2.5em}
\chemnameinit{}
 \chemname{\chemfig{H_{3}C-N([1]-CH_3)([7]-CH_3)}}{\small trimethylamine}
\hspace{2em}
\chemname{\chemfig{{\color{red}R}-C([1]=O)([7]-OH)}}{\small carboxylic acid}
\hspace{2em}
 \chemname{\chemfig{H!x!x}}{\small butyl group}
\hspace{2em}
 \chemname{\chemfig{H_{2}C^{+}-HC=CH-C([1]=O)([7]-OH)}}{\small 85 m/z}
\end{center}
#+END_EXPORT


#+CAPTION[]:Precursor Ion Scan
#+NAME: fig:pis
#+ATTR_LaTeX: :width 0.9\textwidth
#+BEGIN_EXPORT LaTeX
\begin{center}
\begin{tikzpicture}
\node[box](ms1)[]{};
\node[label](ms1u)[above=of ms1,yshift=-2em]{MS1};
\node[label](ms1l)[below=of ms1,yshift=2em]{scanning};
\node[box](cc)[right= of ms1]{};
\node[label](ccu)[above=of cc,yshift=-2em]{Collision Cell};
\node[label](ccl)[below=of cc,yshift=2em]{fragmentation};
\node[box](ms2)[right= of cc]{};
\node[label](ms2u)[above=of ms2,yshift=-2em]{MS2};
\node[label](ms2l)[below=of ms2,yshift=2em]{85 m/z};
\draw[->](ms1) -- (cc);
\draw[->](cc) -- (ms2);

%ms1
\draw [gray,->, decorate,decoration=snake] (-.8,0.5) -- (.8,0.5);
\draw [gray,->, decorate,decoration=snake] (-.8,0.25) -- (.8,0.25);
\draw [blue, ->, decorate,decoration=snake] (-.8, 0) -- (.8,0);
\draw [gray,->, decorate,decoration=snake] (-.8,-0.25) -- (.8,-0.25);
\draw [gray,->, decorate,decoration=snake] (-.8,-0.5) -- (.8,-0.5);

%cc
\draw [blue,->,decorate,decoration=snake] (2.1, 0) -- (2.4,0);
\fill (2.6,0) circle (0.1); 
\draw [gray,->,decorate,decoration=snake] (2.8, 0) -- (3.8,0.5);
\draw [red, ->,decorate,decoration=snake] (2.8, 0) -- (3.8,0);
\draw [gray,->,decorate,decoration=snake] (2.8, 0) -- (3.8,-0.5);

%ms2
\draw [red,->,decorate,decoration=snake] (6.0, 0) -- (7.7,0);
\end{tikzpicture}
\end{center}
#+END_EXPORT


** Overestimation of Free Carnitine
- butylated acylcarnitines are converted to butylated carnitine in
  n-butanol-3M HCl at 65\degree{}C [fn:johnson]

#+CAPTION[]:Overestimation of Free Carnitine
#+NAME: tab:c0
| Acyl Carnitine | Half-life (min) |
|----------------+-----------------|
| C2             |              31 |
| C10            |             125 |
| C18            |             172 |

- 65\degree{}C for 15 min.  
- NSO uses 60\degree{}C for 20 minutes.
- IMD uses 55\degree{}C for 20 minutes.

- in a sample with low free carnitine and high acetylcarnitine
  - 30% of the acetylcarnitine and smaller amounts of higher
    molecular mass acylcarnitines are converted to carnitine
  - a low carnitine sample could appear to be normal
- "the free carnitine results obtained by this screening method on
  blood spots with high levels of acylcarnitines should therefore be
  used with caution" [fn:johnson]

[fn:johnson] Johnson, D. W. (1999). Inaccurate measurement of free
carnitine by the electrospray tandem mass spectrometry screening
method for blood spots. Journal of Inherited Metabolic Disease, 22(2),
201â€“202. 


* Free and Total Carnitine
- acylcarnitine quantitation must be done using a non-derivatized FIA
  or LC MS/MS method
  - avoids acid hydrolysis of acylcarnitines to free carnitine (C0)

\[
\frac{free_{carnitine}}{total_{carnitine}} = \frac{C_0}{\sum_{0}^{18} C_n}
\]

- \Downarrow in CUD \lt 5-10% of normal 


** Fractional Tubular Re-absorption of Carnitine

#+BEGIN_EXPORT LaTeX
\begin{equation*}
FTR_{carnitine}\% = \left( 1 -  \frac{carnitine_{urine} \cdot creatinine_{plasma}}{carnitine_{plasma} \cdot creatinine_{urine}}\right) \cdot 100
\end{equation*}
#+END_EXPORT

- \Downarrow in CUD normally \gt 98%


